Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver
References (36)
- et al.
General and regional circulatory alterations in cirrhosis of the liver
Am J Med
(1964) - et al.
Circulatory changes in chronic liver disease
Am J Med
(1958) - et al.
Epoprostenol (prostacyclin, PGI2) increases apparent liver blood flow in man
Prostaglandins Leukotrienes Med
(1983) - et al.
Wedged and free hepatic venous pressure with a balloon catheter
Gastroenterology
(1979) - et al.
Measurement of portal pressure and its clinical application
Am J Med
(1970) - et al.
Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites
Gastroenterology
(1983) - et al.
Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator effects
Gastroenterology
(1983) Role of prostaglandins in renin secretion
Kidney Int
(1981)- et al.
Hepatic blood flow in alcoholic liver disease measured by an indicator dilution technique
Am J Med
(1972) - et al.
Hepatic and systemic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis
Relationship of systemic and intrarenal hemodynamics in cirrhosis
J Lab Clin Med
Vasoactive intestinal polypeptide (VIP) in cirrhosis: arteriovenous extraction in different vascular beds
Scand J Gastroenterol
Influence of indomethacin and of prostaglandin E1 on total and regional blood flow in man
Acta Physiol Scand
Dissimilar effect of prostacyclin on cardiac output and forearm blood flow in healthy man
Clin Physiol
Influence of primary prostaglandins, prostacyclin and arachidonic acid on mesenteric hemodynamics in the pig
Prostaglandins Med
Circulation times in the splanchnic and hepatic beds in alcoholic liver disease
Gastroenterology
Portal venous inflow modulates portal hypertension in cirrhotic rats: further evidence for the “forward flow” theory (abstr)
Gastroenterology
Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis on the liver: comparison with vasopressin
Gastroenterology
Cited by (132)
Review: The Perioperative Use of Thromboelastography for Liver Transplant Patients
2018, Transplantation ProceedingsCitation Excerpt :Evidence suggests that hepatic fibrosis contributes to decreased thrombopoietin levels and decreased platelet production [7]. Liver failure patients also have increased production of nitric oxide and prostaglandin, which contribute to platelet function [8–10]. Additionally, renal dysfunction and uremia often accompany liver failure and contribute to myriad causes of platelet dysfunction [11].
Clinical implications of the hyperdynamic syndrome in cirrhosis
2014, European Journal of Internal MedicinePhysiopathological bases for the use of human albumin in liver cirrhosis
2012, Gastroenterologia y HepatologiaSelective cyclooxygenase inhibition improves hepatic encephalopathy in fulminant hepatic failure of rat
2011, European Journal of PharmacologyPathophysiological basis of albumin use in cirrhosis
2011, Annals of HepatologyCitation Excerpt :When an effective hypovolemia takes place, whether as a result of loss of volume or vasodilation, vasoconstriction systems become activated to maintain blood pressure by acting in these vascular territories.34 In cirrhosis, the regulatory effect of blood pressure, however, occurs preferentially in the kidney, since the splanchnic vasculature is highly resistant to the effect of endogenous vasoconstrictors due to the massive release of vasodilator substances occurring in the vascular compartment.19-25 It is also possible that newly formed vessels in the splanchnic area do not react with the required intensity.
Pulmonary Complications of Cirrhosis
2009, Medical Clinics of North America
This work was supported by grants from the Fondo de Investigaciones Sanitarias de la Seguridad Social (82/412, 82/264) and from the Comisión Asesora de Investigación Científica y Técnica, Ministerio de Educatión y Ciencia.
This work was presented at the 18th Meeting of the European Association for the Study of the Liver, Southampton (U.K.), September 1–3, 1983.